HDC Inhibitors

The inhibitors listed here predominantly target histamine-related processes rather than directly inhibiting HDC. However, Alpha-Fluoromethylhistidine (FMH) stands out as a specific and irreversible inhibitor of HDC, making it a significant compound for directly reducing histamine synthesis. The other compounds, such as Loratadine, Diphenhydramine, Chlorpheniramine, and Doxylamine, are antihistamines that block the action of histamine at its receptors. H2 receptor antagonists like Cimetidine, Famotidine, and Ranitidine are specifically used to reduce gastric acid secretion in conditions like peptic ulcers and gastroesophageal reflux disease (GERD). They work by blocking the action of histamine on the H2 receptors of gastric parietal cells, indirectly influencing the role of histamine produced by HDC in the stomach. Proton pump inhibitors (PPIs) like Omeprazole also impact gastric acid secretion but through a different mechanism than H2 antagonists. While PPIs do not directly inhibit HDC, they reduce the stomach's overall acid production, which is partially regulated by histamine. Azelastine and Ketotifen, in addition to their antihistamine properties, have additional actions such as mast cell stabilization, which can further reduce histamine release and its effects.